Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen
Author:
Publisher
Baishideng Publishing Group Inc.
Subject
Oncology
Reference32 articles.
1. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
2. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents
3. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme
4. Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance
5. Use ofCYP2D6genotyping in practice: tamoxifen dose adjustment
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies;Molecules;2023-05-23
2. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes;The Pharmacogenomics Journal;2017-08-01
3. Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer;Amino Acids;2016-07-20
4. Incidence of inactive allele CYP2D6*4 among Greek women suffering from hormone-sensitive breast cancer;EUR J GYNAECOL ONCOL;2016
5. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status;BMC Cancer;2015-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3